Synribo (Chronic Myeloid Leukemia)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
3 Disease Overview 9
3.1 Etiology and Pathophysiology 9
3.1.1 Etiology 9
3.1.2 Pathophysiology 10
3.1.3 Clinical Staging 11
3.1.4 Prognosis 13
3.1.5 Quality of Life 14
3.2 Symptoms 15
4 Disease Management 16
4.1 Global Trends 16
4.1.1 Treatment Overview 16
4.1.2 Diagnostic Tests 19
4.1.3 Genetic Testing 20
4.1.4 Monitoring Patient Response to Treatment 22
4.1.5 Future Directions: Discontinuation Therapy 25
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
6 Product Profile – Synribo (omacetaxine mepesuccinate) 31
6.1 Overview 31
6.2 Efficacy 33
6.3 Safety 33
6.4 SWOT Analysis 34
6.5 Forecast 35
7 Appendix 36
7.1 Bibliography 36
7.2 Abbreviations 38
7.3 Methodology 41
7.4 Forecasting Methodology 41
7.4.1 Diagnosed CML patients 41
7.4.2 Drug-treated Patients on X Line of Therapy 42
7.4.3 General Pricing Assumptions 42
7.4.4 Individual Drug Assumptions 43
7.4.5 Generic Erosion 43
7.5 Physicians and Specialists Included in this Study 44
7.6 Survey of High Prescribing Physicians 45
7.7 About the Authors 46
7.7.1 Authors 46
7.7.2 Epidemiologists 47
7.7.3 Global Director of Epidemiology and Clinical Trials Analysis 48
7.7.4 Global Head of Healthcare 49
7.8 About GlobalData 50
7.9 Contact Us 50
7.10 Disclaimer 50